Passage Bio
PASG
44 hedge funds and large institutions have $27.1M invested in Passage Bio in 2024 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 8 closing their positions.
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
2% more funds holding
Funds holding: 43 → 44 (+1)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.14% less ownership
Funds ownership: 3.27% → 3.13% (-0.14%)
15% less capital invested
Capital invested by funds: $32M → $27.1M (-$4.93M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$2.68M |
| 2 |
Renaissance Technologies
New York
|
+$213K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$194K |
| 4 |
SC
Shay Capital
New York
|
+$73.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$3.2M |
| 2 |
Millennium Management
New York
|
-$467K |
| 3 |
AI
Acuitas Investments
Seattle,
Washington
|
-$375K |
| 4 |
O
OrbiMed
New York
|
-$240K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$210K |
PASG Hedge Fund Activity: Q3 2024 in Review
44 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q3 2024, worth a combined $27.1M — down 15% from $32M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new PASG positions and 8 closed out — a net gain of 1 holder — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $2.68M. The largest seller was Versant Venture Management, exiting entirely with an estimated $3.2M sold.
- 44 institutional investors held Passage Bio (PASG) as of Q3 2024, up from 43 in Q2 2024.
- Funds reported $27.1M of Passage Bio stock for Q3 2024, down 15% quarter-over-quarter.
- 9 funds opened new Passage Bio positions in Q3 2024 and 8 closed out, a net change of +1 holder.
- The largest Passage Bio buyer in Q3 2024 was Lynx1 Capital Management, an estimated $2.68M added.
- The largest Passage Bio seller in Q3 2024 was Versant Venture Management, an estimated $3.2M sold.
Based on aggregated 13F filings for Q3 2024.